A new report published by the HDA Research Foundation entitled The Role of Reverse Distribution provides insights into the reverse distribution of pharmaceutical products. The Foundation estimates that this channel accounts for 3.5 to 4 percent of all pharmaceutical sales — more than 120 million product units — and exceeds $13 billion in product value.
Healthcare Distribution Alliance (HDA) President and CEO John M. Gray released the following statement on the Department of Health and Human Services’ (HHS) recent directive to establish a Food and Drug Administration (FDA) work group to examine prescription drug importation policies.
In response to a new report from Sen. Claire McCaskill (D-Mo.) regarding the role of distributors in addressing the country’s opioid abuse epidemic, Healthcare Distribution Alliance (HDA) President and CEO John M. Gray issued the following statement.
Over the last year, 60 Minutes, in partnership with The Washington Post, has presented several misleading, inaccurate accounts of pharmaceutical distributors’ role in the opioid crisis, including the subsequent enforcement of The Ensuring Patient Access and Effective Drug Enforcement Act. To understand the country’s opioid epidemic and the solutions needed to reduce diversion and misuse of prescription opioids, we need to separate fact from fiction.
Today, the Healthcare Distribution Alliance (HDA), the national trade association for pharmaceutical distributors, filed suit in the U.S. District Court for the Southern District of New York to block enforcement of New York’s Opioid Stewardship Act. The act imposes an unconstitutional $600 million punitive surcharge on pharmaceutical distributors and manufacturers. It bypasses judicial due process and impedes the industry’s comprehensive efforts to mitigate opioid abuse and misuse.
John Parker
(703) 885-0216
Farah Simonett
(703) 885-0269
